54 related articles for article (PubMed ID: 29966681)
1. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
2. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of Prostate cancer].
Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
[No Abstract] [Full Text] [Related]
3. A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes.
Wang J; Jiang L; Shang Z; Ye Z; Yuan D; Cui X
Cancer Biother Radiopharm; 2024 May; 39(4):306-317. PubMed ID: 37610864
[No Abstract] [Full Text] [Related]
4. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.
Wang Q; Ye Y; Yu H; Lin SH; Tu H; Liang D; Chang DW; Huang M; Wu X
Cancer Immunol Immunother; 2021 Mar; 70(3):701-712. PubMed ID: 32909077
[TBL] [Abstract][Full Text] [Related]
5. An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes.
Thiemeyer H; Taher L; Schille JT; Packeiser EM; Harder LK; Hewicker-Trautwein M; Brenig B; Schütz E; Beck J; Nolte I; Murua Escobar H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768937
[TBL] [Abstract][Full Text] [Related]
6. Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing.
Ma X; Guo J; Liu K; Chen L; Liu D; Dong S; Xia J; Long Q; Yue Y; Zhao P; Hu F; Xiao Z; Pan X; Xiao K; Cheng Z; Ke Z; Chen ZS; Zou C
Mol Cancer; 2020 Oct; 19(1):147. PubMed ID: 33032611
[TBL] [Abstract][Full Text] [Related]
7. Identification of methylation driver genes for predicting the prognosis of pancreatic cancer patients based on whole-genome DNA methylation sequencing technology.
Song C; Wang G; Liu M; Xu Z; Liang X; Ding K; Chen Y; Wang W; Lou W; Liu L
Heliyon; 2024 May; 10(9):e29914. PubMed ID: 38737285
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation markers for risk of metastasis in a cohort of men with localized prostate cancer.
Habeshian TS; Cannavale KL; Slezak JM; Shu YH; Chien GW; Chen X; Shi F; Siegmund KD; Van Den Eeden SK; Huang J; Chao CR
Epigenetics; 2024 Dec; 19(1):2308920. PubMed ID: 38525786
[TBL] [Abstract][Full Text] [Related]
9. Human Prostate Cancer is Characterized by an Increase in Urea Cycle Metabolites.
Franko A; Shao Y; Heni M; Hennenlotter J; Hoene M; Hu C; Liu X; Zhao X; Wang Q; Birkenfeld AL; Todenhöfer T; Stenzl A; Peter A; Häring HU; Lehmann R; Xu G; Lutz SZ
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32640711
[TBL] [Abstract][Full Text] [Related]
10. Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer.
Wiesmueller F; Kopke J; Aust D; Roy J; Dahl A; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683647
[TBL] [Abstract][Full Text] [Related]
11. Identification of Potential Key Genes for Pathogenesis and Prognosis in Prostate Cancer by Integrated Analysis of Gene Expression Profiles and the Cancer Genome Atlas.
Liu S; Wang W; Zhao Y; Liang K; Huang Y
Front Oncol; 2020; 10():809. PubMed ID: 32547947
[No Abstract] [Full Text] [Related]
12. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
Ye Y; Li SL; Wang SY
PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
[TBL] [Abstract][Full Text] [Related]
13. Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients.
Miller BF; Petrykowska HM; Elnitski L
Sci Rep; 2021 Jan; 11(1):221. PubMed ID: 33420235
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
Wu L; Quan W; Yue G; Luo Q; Peng D; Pan Y; Zhang G
BMC Cancer; 2021 Jan; 21(1):15. PubMed ID: 33402116
[TBL] [Abstract][Full Text] [Related]
15. Association study between genetic variants in retinol metabolism pathway genes and prostate cancer risk.
Cao D; Meng Y; Li S; Xin J; Ben S; Cheng Y; Wang M; Hua L; Cheng G
Cancer Med; 2020 Dec; 9(24):9462-9470. PubMed ID: 33068330
[TBL] [Abstract][Full Text] [Related]
16. PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target.
Wang J; Wang L; Chen S; Peng H; Xiao L; E Du ; Liu Y; Lin D; Wang Y; Xu Y; Yang K
Gene; 2020 Jun; 744():144608. PubMed ID: 32234541
[TBL] [Abstract][Full Text] [Related]
17. Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer.
Zhang N; Chen S; Wu L; Wu Y; Jiang G; Shao J; Chen L; Sun J; Na R; Wang X; Xu J
J Cancer; 2019; 10(26):6761-6766. PubMed ID: 31777606
[TBL] [Abstract][Full Text] [Related]
18. Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma.
Mishra NK; Southekal S; Guda C
Front Genet; 2019; 10():624. PubMed ID: 31379917
[TBL] [Abstract][Full Text] [Related]
19. Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.
Foj L; Filella X
Pathol Oncol Res; 2019 Oct; 25(4):1445-1456. PubMed ID: 30367364
[TBL] [Abstract][Full Text] [Related]
20. Evaluating Stacked Methylation Markers for Blood-Based Multicancer Detection.
Funderburk K; Bang-Christensen SR; Miller BF; Tan H; Margolin G; Petrykowska HM; Baugher C; Farney SK; Grimm SA; Jameel N; Holland DO; Altman NS; Elnitski L
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
